Clene Inc. (CLNN) - Total Liabilities
Based on the latest financial reports, Clene Inc. (CLNN) has total liabilities worth $40.47 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Clene Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how Clene Inc.'s total liabilities have evolved over time, based on quarterly financial data. See CLNN net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Clene Inc. Competitors by Total Liabilities
The table below lists competitors of Clene Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Titijaya Land Bhd
KLSE:5239
|
Malaysia | RM1.08 Billion |
|
DaChan Food (Asia) Limited
F:3DS
|
Germany | €1.29 Billion |
|
CKM Building Material
TWO:8930
|
Taiwan | NT$591.98 Million |
|
SBI Investment KOREA Co. Ltd
KQ:019550
|
Korea | ₩4.14 Billion |
|
ESTec Corporation
KQ:069510
|
Korea | ₩127.62 Billion |
|
Metro Systems Corporation Public Company Limited
BK:MSC
|
Thailand | ฿2.08 Billion |
|
Roo Hsing Co Ltd
TW:4414
|
Taiwan | NT$8.37 Billion |
|
Surf Air Mobility Inc.
NYSE:SRFM
|
USA | $199.34 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Clene Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CLNN market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Clene Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Clene Inc. (2018–2025)
The table below shows the annual total liabilities of Clene Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $35.72 Million | -1.30% |
| 2024-12-31 | $36.19 Million | -7.08% |
| 2023-12-31 | $38.95 Million | -5.59% |
| 2022-12-31 | $41.26 Million | -18.25% |
| 2021-12-31 | $50.47 Million | -25.68% |
| 2020-12-31 | $67.90 Million | +579.70% |
| 2019-12-31 | $9.99 Million | -76.31% |
| 2018-12-31 | $42.16 Million | -- |
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral … Read more